TYRX, Inc. raises $20 million in private financing

TYRX, Inc. raises $20 million in private financing

 

Proceeds will Support Continued Commercialization of the AIGISRx® Antibacterial Envelope and Development of Next Generation Products

Monmouth Junction, NJ (December 8, 2010) – TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections associated with implantable pacemakers and defibrillators, announced today that it has raised $20 million in venture capital funding. The funding was led by new investor, HLM Venture Partners along with previous investors Clarus Ventures and Pappas Ventures. The financing round also included $4 million in debt financing from Comerica Bank. In connection with the financing, Edward L. Cahill, Managing Partner, HLM Venture Partners, will join TYRX’s Board of Directors.

"Plexxikon - 2010 Fierce 15" - FierceBiotech

 
September 15, 2010

With pharma focused on new frontline therapies, developers are relying on new technology to advance a fresh series of best-in-class therapies--anything that looks like a me-too approach won't get pushed. And Plexxikon hit paydirt when it collected a $60 million upfront from Roche in early 2009 pact covering its PLX-5568, an experimental therapy for a rare genetic kidney disease as well as additional undisclosed programs. Altogether the developer has rounded up a whopping $185 million in non-dilutive partnership funding, a stellar record in an industry that thrives on that kind of cash.

GE Healthcare forms strategic alliance with cardiovascular genomic diagnostic company, CardioDx

 

Fairfield, CT, USA – May 13, 2010 — GE Healthcare, the healthcare business of GE (NYSE: GE) and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease. Building on the alliance, the GE Healthymagination Fund, a new equity fund that makes investments in highly promising healthcare technology companies, has invested $5 million in CardioDx as part of a Series D round that the fund is leading. The alliance between the two companies aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare. This marks the first investment for the HealthymaginationFund. Otherfinancialtermswerenotdisclosed.

FDA provides clearance of TyRx antibacterial patch for soft tissue repair

 

MONMOUTH JUNCTION, N.J., April 27, 2010 --(BUSINESS WIRE)-- TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market AIGISRx® ST , its antibacterial product for the surgical repair of damaged or ruptured soft tissue.

TYRX had previously received 510(k) clearance to market a product for hernia repair and other abdominal soft tissue deficiencies. The new clearance adds the use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue. AIGISRx ST delivers the antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.

Liquidia Technologies has added an additional investor, PPD, Inc., to its Series C financing

 

RESEARCH TRIANGLE PARK, N.C., April 20, 2010 --(EON: Enhanced Online News)-- Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.

New Anti-Bacterial Device Helps Reduce Infections Associated with Pacemaker and Defibrillator Implantation

 

Monmouth Junction, NJ, (April 13, 2010) -- TYRX, Inc. announced today the commercial release of the AIGISRx® Flat, an antibacterial product that helps provide protection against infections associated with implanted pacemakers and defibrillators.

Like the original AIGISRx™ Envelope, AIGISRx Flat delivers the anti-microbial agents, rifampin and minocycline which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm management device (CRMD)-related endocarditis, including “superbugs” or MRSA. AIGISRx Flat also offers the implanting physician additional flexibility in the application of these lifesaving devices.

"The Business of Biotechnology"

All companies — large and small, biotech included — have felt the pinch of the current (or recent, depending on your point of view) recession. From huge multinational companies to virtual start-ups, all are taking a good hard look at the way they do business. And as it does every year, the 2010 BIO International Convention will offer something for every company and every situation. Business-oriented sessions range from hard-earned experience to provocative new ideas.

BioMarin to acquire LEAD Therapeutics

 

NOVATO, Calif., Feb 04, 2010 /PRNewswire via COMTEX/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.

Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals

 
Pappas, Third Rock, Domain and New Leaf Launch New Company Centered on Novel Pain
Management Technology; Afferent to Initiate Clinical Trials in First Half of 2010

Basel, Switzerland and Palo Alto, Calif., 16 December 2009 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has licensed its P2X3i receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway. In conjunction with this announcement, Afferent successfully closed a $23 million Series A financing, which was led by Third Rock Ventures and Pappas Ventures, and included Domain Associates and New Leaf Venture Partners. Proceeds from the financing will be used to accelerate the development of P2X3 receptor targeted pain therapies.